脂蛋白(a)的研究进展

脂蛋白(a)是动脉粥样硬化形成与进展的高危因素,外周血中高浓度的脂蛋白(a)已成为冠心病公认的预测因子。由于它主要受遗传调控,饮食、运动、生活方式、传统降脂药物等对脂蛋白(a)水平的影响很小。随着研究的深入,脂蛋白(a)的代谢、致病机制和危害逐渐被人们了解,氧化修饰后的脂蛋白(a)具有更强的致动脉粥样硬化作用。此外,可降低脂蛋白(a)的新型降脂药物已经被研发出来,它们降低脂蛋白(a)的强度和作用靶点各不相同,对疾病的预后的影响也仍有待观察。本文就脂蛋白(a)的代谢、遗传调控、氧化修饰、临床干预手段等研究进展作一综述。

Research progress of lipoprotein(a)

Lipoprotein(a) is a high risk factor for the formation and progression of atherosclerosis, and high level of lipoprotein(a) has been confirmed as a predictor of coronary heart disease. Because it is mainly controlled by genetics, diet, exercise, lifestyle, traditional lipid-lowering drugs have little effect on lipoprotein(a) level. With the deepening research, the metabolism, pathogenesis and harm of lipoprotein(a) have been gradually understood. Oxidized modified lipoprotein(a) has a stronger atherogenic effect. New lipid lowering drugs that reduce lipoprotein(a) have been developed, each of them has different target, functional intensity and mechanism of action on lowering lipoprotein(a), and the effect on the prognosis of the disease remains to be observed. This paper reviews the research progress of lipoprotein(a) metabolism, genetic regulation, oxidative modification and clinical intervention.